Literature DB >> 10136585

The relationship of antipsychotic drug use, behavior, and diagnoses among nursing home residents.

D L Spore1, A L Horgas, M A Smyer, L N Marks.   

Abstract

Nursing homes have been criticized for frequent use and possible misuse of psychoactive agents. These issues are of clinical concern and policy relevance, especially since the passage of the Omnibus Budget Reconciliation Act (OBRA) of 1987. Using a sample of 419 residents, the authors examined the relationships among antipsychotic drug (AP) use, behavior, and mental health diagnoses. Only 23.2% of the residents were administered APs on a routine and/or "as-needed" basis. Based on the Multidimensional Observation Scale for Elderly Subjects (MOSES) ratings, AP users were more irritable, disoriented, and withdrawn than were nonusers. Also, AP users demonstrated agitated behaviors more frequently. Notably, AP users and nonusers differed significantly in terms of documented mental health diagnoses. Among AP users, 70.1% had documented dementia, 8.3% were psychotic or had other psychiatric disorders, and 21.6% had no mental health diagnoses. In contrast, the majority of nonusers had no mental health disorders. Logistic regression revealed that diagnostic factors, frequency of agitation, level of withdrawal, and marital status were significant predictors of AP use.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 10136585     DOI: 10.1177/089826439200400404

Source DB:  PubMed          Journal:  J Aging Health        ISSN: 0898-2643


  2 in total

1.  The effects of public reporting on physical restraints and antipsychotic use in nursing home residents with severe cognitive impairment.

Authors:  R Tamara Konetzka; Daniel J Brauner; Joseph Shega; Rachel M Werner
Journal:  J Am Geriatr Soc       Date:  2014-03-11       Impact factor: 5.562

2.  Medications use among women with dementia: a cohort study.

Authors:  Kailash Thapaliya; Melissa L Harris; Peta M Forder; Julie E Byles
Journal:  Aging Clin Exp Res       Date:  2021-05-26       Impact factor: 3.636

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.